Cargando…

Clinical evaluation of the SD Biosensor SARS-CoV-2 saliva antigen rapid test with symptomatic and asymptomatic, non-hospitalized patients

BACKGROUND: Performance of the SD Biosensor saliva antigen rapid test was evaluated at a large designated testing site in non-hospitalized patients, with or without symptoms. METHOD: All eligible people over 18 years of age presenting for a booked appointment at the designated SARS-CoV-2 testing sit...

Descripción completa

Detalles Bibliográficos
Autores principales: Igloi, Zsofia, Velzing, Jans, Huisman, Robin, Geurtsvankessel, Corine, Comvalius, Anoushka, IJpelaar, Jeroen, van Beek, Janko, Ensing, Roel, Boelsums, Timo, Koopmans, Marion, Molenkamp, Richard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8694432/
https://www.ncbi.nlm.nih.gov/pubmed/34936659
http://dx.doi.org/10.1371/journal.pone.0260894
_version_ 1784619354344652800
author Igloi, Zsofia
Velzing, Jans
Huisman, Robin
Geurtsvankessel, Corine
Comvalius, Anoushka
IJpelaar, Jeroen
van Beek, Janko
Ensing, Roel
Boelsums, Timo
Koopmans, Marion
Molenkamp, Richard
author_facet Igloi, Zsofia
Velzing, Jans
Huisman, Robin
Geurtsvankessel, Corine
Comvalius, Anoushka
IJpelaar, Jeroen
van Beek, Janko
Ensing, Roel
Boelsums, Timo
Koopmans, Marion
Molenkamp, Richard
author_sort Igloi, Zsofia
collection PubMed
description BACKGROUND: Performance of the SD Biosensor saliva antigen rapid test was evaluated at a large designated testing site in non-hospitalized patients, with or without symptoms. METHOD: All eligible people over 18 years of age presenting for a booked appointment at the designated SARS-CoV-2 testing site were approached for inclusion and enrolled following verbal informed consent. One nasopharyngeal swab was taken to carry out the default antigen rapid test from which the results were reported back to the patient and one saliva sample was self-taken according to verbal instruction on site. This was used for the saliva antigen rapid test, the RT-PCR and for virus culture. Sensitivity of the saliva antigen rapid test was analyzed in two ways: i, compared to saliva RT-PCR; and ii, compared to virus culture of the saliva samples. Study participants were also asked to fill in a short questionnaire stating age, sex, date of symptom onset. Recommended time of ≥30mins since last meal, drink or cigarette if applicable was also recorded. The study was carried out in February-March 2021 for 4 weeks. RESULTS: We could include 789 people with complete records and results. Compared to saliva RT-PCR, overall sensitivity and specificity of the saliva antigen rapid test was 66.1% and 99.6% which increased to 88.6% with Ct ≤30 cutoff. Analysis by days post onset did not result in higher sensitivities because the large majority of people were in the very early phase of disease ie <3 days post onset. When breaking down the data for symptomatic and asymptomatic individuals, sensitivity ranged from 69.2% to 50% respectively, however the total number of RT-PCR positive asymptomatic participants was very low (n = 5). Importantly, almost all culture positive samples were detected by the rapid test. CONCLUSION: Overall, the potential benefits of saliva antigen rapid test, could outweigh the lower sensitivity compared to nasopharyngeal antigen rapid test in a comprehensive testing strategy, especially for home/self-testing and in vulnerable populations like elderly, disabled or children where in intrusive testing is either not possible or causes unnecessary stress.
format Online
Article
Text
id pubmed-8694432
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-86944322021-12-23 Clinical evaluation of the SD Biosensor SARS-CoV-2 saliva antigen rapid test with symptomatic and asymptomatic, non-hospitalized patients Igloi, Zsofia Velzing, Jans Huisman, Robin Geurtsvankessel, Corine Comvalius, Anoushka IJpelaar, Jeroen van Beek, Janko Ensing, Roel Boelsums, Timo Koopmans, Marion Molenkamp, Richard PLoS One Research Article BACKGROUND: Performance of the SD Biosensor saliva antigen rapid test was evaluated at a large designated testing site in non-hospitalized patients, with or without symptoms. METHOD: All eligible people over 18 years of age presenting for a booked appointment at the designated SARS-CoV-2 testing site were approached for inclusion and enrolled following verbal informed consent. One nasopharyngeal swab was taken to carry out the default antigen rapid test from which the results were reported back to the patient and one saliva sample was self-taken according to verbal instruction on site. This was used for the saliva antigen rapid test, the RT-PCR and for virus culture. Sensitivity of the saliva antigen rapid test was analyzed in two ways: i, compared to saliva RT-PCR; and ii, compared to virus culture of the saliva samples. Study participants were also asked to fill in a short questionnaire stating age, sex, date of symptom onset. Recommended time of ≥30mins since last meal, drink or cigarette if applicable was also recorded. The study was carried out in February-March 2021 for 4 weeks. RESULTS: We could include 789 people with complete records and results. Compared to saliva RT-PCR, overall sensitivity and specificity of the saliva antigen rapid test was 66.1% and 99.6% which increased to 88.6% with Ct ≤30 cutoff. Analysis by days post onset did not result in higher sensitivities because the large majority of people were in the very early phase of disease ie <3 days post onset. When breaking down the data for symptomatic and asymptomatic individuals, sensitivity ranged from 69.2% to 50% respectively, however the total number of RT-PCR positive asymptomatic participants was very low (n = 5). Importantly, almost all culture positive samples were detected by the rapid test. CONCLUSION: Overall, the potential benefits of saliva antigen rapid test, could outweigh the lower sensitivity compared to nasopharyngeal antigen rapid test in a comprehensive testing strategy, especially for home/self-testing and in vulnerable populations like elderly, disabled or children where in intrusive testing is either not possible or causes unnecessary stress. Public Library of Science 2021-12-22 /pmc/articles/PMC8694432/ /pubmed/34936659 http://dx.doi.org/10.1371/journal.pone.0260894 Text en © 2021 Igloi et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Igloi, Zsofia
Velzing, Jans
Huisman, Robin
Geurtsvankessel, Corine
Comvalius, Anoushka
IJpelaar, Jeroen
van Beek, Janko
Ensing, Roel
Boelsums, Timo
Koopmans, Marion
Molenkamp, Richard
Clinical evaluation of the SD Biosensor SARS-CoV-2 saliva antigen rapid test with symptomatic and asymptomatic, non-hospitalized patients
title Clinical evaluation of the SD Biosensor SARS-CoV-2 saliva antigen rapid test with symptomatic and asymptomatic, non-hospitalized patients
title_full Clinical evaluation of the SD Biosensor SARS-CoV-2 saliva antigen rapid test with symptomatic and asymptomatic, non-hospitalized patients
title_fullStr Clinical evaluation of the SD Biosensor SARS-CoV-2 saliva antigen rapid test with symptomatic and asymptomatic, non-hospitalized patients
title_full_unstemmed Clinical evaluation of the SD Biosensor SARS-CoV-2 saliva antigen rapid test with symptomatic and asymptomatic, non-hospitalized patients
title_short Clinical evaluation of the SD Biosensor SARS-CoV-2 saliva antigen rapid test with symptomatic and asymptomatic, non-hospitalized patients
title_sort clinical evaluation of the sd biosensor sars-cov-2 saliva antigen rapid test with symptomatic and asymptomatic, non-hospitalized patients
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8694432/
https://www.ncbi.nlm.nih.gov/pubmed/34936659
http://dx.doi.org/10.1371/journal.pone.0260894
work_keys_str_mv AT igloizsofia clinicalevaluationofthesdbiosensorsarscov2salivaantigenrapidtestwithsymptomaticandasymptomaticnonhospitalizedpatients
AT velzingjans clinicalevaluationofthesdbiosensorsarscov2salivaantigenrapidtestwithsymptomaticandasymptomaticnonhospitalizedpatients
AT huismanrobin clinicalevaluationofthesdbiosensorsarscov2salivaantigenrapidtestwithsymptomaticandasymptomaticnonhospitalizedpatients
AT geurtsvankesselcorine clinicalevaluationofthesdbiosensorsarscov2salivaantigenrapidtestwithsymptomaticandasymptomaticnonhospitalizedpatients
AT comvaliusanoushka clinicalevaluationofthesdbiosensorsarscov2salivaantigenrapidtestwithsymptomaticandasymptomaticnonhospitalizedpatients
AT ijpelaarjeroen clinicalevaluationofthesdbiosensorsarscov2salivaantigenrapidtestwithsymptomaticandasymptomaticnonhospitalizedpatients
AT vanbeekjanko clinicalevaluationofthesdbiosensorsarscov2salivaantigenrapidtestwithsymptomaticandasymptomaticnonhospitalizedpatients
AT ensingroel clinicalevaluationofthesdbiosensorsarscov2salivaantigenrapidtestwithsymptomaticandasymptomaticnonhospitalizedpatients
AT boelsumstimo clinicalevaluationofthesdbiosensorsarscov2salivaantigenrapidtestwithsymptomaticandasymptomaticnonhospitalizedpatients
AT koopmansmarion clinicalevaluationofthesdbiosensorsarscov2salivaantigenrapidtestwithsymptomaticandasymptomaticnonhospitalizedpatients
AT molenkamprichard clinicalevaluationofthesdbiosensorsarscov2salivaantigenrapidtestwithsymptomaticandasymptomaticnonhospitalizedpatients